Haemonetics Corporation (NYSE:HAE) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET

Company Participants

Olga Guyette – Vice President, Investor Relations and Treasury
Chris Simon – Chief Executive Officer
James D’Arecca – Chief Financial Officer

Conference Call Participants

Anthony Petrone – Mizuho Americas
Mike Matson – Needham
Andrew Cooper – Raymond James
Larry Solow – CJS Securities
Joanne Wuensch – Citi
Michael Petusky – Barrington Research

Operator

Thank you for standing by, and welcome to Haemonetics Corporation’s First Quarter Fiscal Year 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the call over to Olga Guyette, Vice President, Investor Relations and Treasury. Please go ahead.

Olga Guyette

Good morning, everyone. Thank you for joining us for Haemonetics first quarter fiscal year 2025 conference call and webcast. I’m joined today by Chris Simon, our CEO; and James D’Arecca, our CFO. This morning, we posted our first quarter fiscal year 2025 results to our Investor Relations website along with our fiscal 2025 guidance.

Before we begin, a quick reminder that all revenue growth rates discussed today are organic unless specified otherwise, and exclude the impact of currency fluctuation and acquisitions. Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from OpSens due to the acquisition closing date being in December 2023. We’ll also refer to other non-GAAP financial measures to help investors understand Haemonetics ongoing business performance.

Please note that these measures exclude certain charges and income items. For a full list of excluded items, reconciliations to our GAAP results and comparisons with the prior year periods, please refer to our first quarter fiscal year 2025 earnings release available on our website. Our remarks today include forward-looking statements and our actual results may differ materially from anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today’s earnings release, and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements.

And now, I’d like to turn it over to Chris.

Chris Simon

Thanks, Olga. Good morning and thank you all for joining. Today, we reported first quarter revenue of $336 million, growth of 8% on a reported basis and 3% organically and adjusted earnings per diluted share of $1.02, a 3% decrease from a strong first quarter in the prior year. The start of our fiscal year reflects the strength in the breadth of our product portfolio, our capacity for continued innovation and growth, and the resilience of our business to succeed in dynamic markets as we navigate ongoing geopolitical challenges.